Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus–Unrelated Head and Neck Cancer: A Multicenter, Phase II TrialRavindra Uppaluri, Douglas R. Adkins, Nicholas C. Spies et al.|Clinical Cancer Research|2020Cited by 368
Validation of a Next-Generation Sequencing Assay for Clinical Molecular OncologyCatherine E. Cottrell, John D. Pfeifer, Hussam Al‐Kateb et al.|Journal of Molecular Diagnostics|2013Cited by 184
Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast CancerMeenakshi Anurag, Matthew J. Ellis, Eric J. Jaehnig et al.|Cancer Discovery|2022Cited by 139
T-cell clonality assessment by next-generation sequencing improves detection sensitivity in mycosis fungoidesKari E. Sufficool, Eric J. Duncavage, Christina M. Lockwood et al.|Journal of the American Academy of Dermatology|2015Cited by 103
A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III <i>PIK3CA</i> -Mutant ER-Positive and HER2-Negative Breast CancerX. Cynthia, Matthew J. Ellis, Vera J. Suman et al.|Clinical Cancer Research|2017Cited by 74